Update shared on30 Aug 2025
Fair value Increased 14%The higher analyst price target for NeoGenomics reflects an expansion in its future P/E multiple despite stable revenue growth forecasts, resulting in a revised fair value of $9.78.
What's in the News
- U.S. District Court invalidated certain Natera patents asserted against NeoGenomics’ RaDaR v1.1 test, but the decision does not affect the '035 patent that previously led to a permanent injunction on RaDaR v1.0.
- NeoGenomics launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test targeting the expanding liquid biopsy market and enhancing its pan-solid tumor CGP portfolio.
- The company lowered full-year 2025 revenue guidance to $720–$726 million from $747–$759 million and widened expected net loss to $108–$116 million vs. prior $77–$85 million loss forecast.
- NeoGenomics launched PanTracer Tissue, a next-generation solid tumor profiling assay, including an option with HRD analysis, enabling guideline-aligned, faster, and more comprehensive tumor testing for therapy selection and clinical trials.
Valuation Changes
Summary of Valuation Changes for NeoGenomics
- The Consensus Analyst Price Target has significantly risen from $8.61 to $9.78.
- The Future P/E for NeoGenomics has significantly risen from 28.53x to 32.39x.
- The Consensus Revenue Growth forecasts for NeoGenomics remained effectively unchanged, at 9.0% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.